STRATA Skin Sciences, Inc. Earnings Recaps
Q3 2025
Nov 14, 2025
STRATA Skin Sciences reported a challenging third quarter with revenues decreasing by 20% year-over-year, largely due to international market pressures, while domestic recurring revenues demonstrate resilience and growth.
Key takeaways
- Total revenue for Q3 2025 was $6.9 million, a decline of 20% compared to Q3 2024, primarily impacted by international trade uncertainties.
- U.S. recurring revenue from XTRAC increased by 2.8%, signaling stability within domestic operations.
- The expanded CPT codes for XTRAC treatments, effective January 2027, offer potential access to over 30 million patients, significantly enlarging the company’s market opportunity.
- The Elevate360 program has driven an average clinic growth rate of 7% year-over-year and improved gross billings per device by 8.5% compared to last year.
- STRATA is pursuing legal action against LaserOptik, anticipating significant damages that could bolster revenue from previously misled clinics.